Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

ENCORE1 Study Group

Research output: Contribution to journalArticlepeer-review

84 Citations (Scopus)

Fingerprint Dive into the research topics of 'Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study'. Together they form a unique fingerprint.

Medicine & Life Sciences